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Summary. To date, only few preclinical protocols on 
liposomal suicide gene transfer in tumors have been 
published, none of which directly compared viral to 
liposomal vectors in terms of immunoreactivity and 
efficacy. We thus studied the neuropathological 
alterations in 80 rats being treated for glioblastoma using 
liposomal and, for comparison, adenoviral and retroviral 
suicide gene transfer approaches to identify vector- 
associated efficacy and toxicity for further clinical 
studies. 62 rats served as controls. F98 tumors were 
established in Fisher rats and transfected in vivo with the 
thymidine kinase gene of herpes simplex virus (HSVtk) 
by a single intratumoral application and an implanted 
intratumoral continuous delivery system. Three days 
later ganciclovir was given intraperitoneally for 14 days. 
The animals were sacrificed 17  days post completed 
gene transfer. Brains were examined histologically and 
immunohistochemically using markers  for  
immunocompetent cells. Ten animals showed complete 
tumor regression; they al1 belonged to the liposomal and 
adenoviral groups. In 6 of 10  experimental groups 
considerable numbers of lymphocytes along the margins 
of the regression cavities could be observed. Control 
animals of the liposomal and adenoviral groups showed 
only little lymphocytic infiltration, underlining the 
minimal immunogenicity of these carriers. In contrast, 
the retroviral control group featured a high lymphocyte 
infiltration. In summary, this study indicates that, in 
terms of both efficacy and immunoreaction, liposomes 
are as appropriate as adenoviruses in the treatment of rat 
glial tumors using suicide gene transfer strategies. 
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lntroduction 
To date, no effective therapy is available to cure 
malignant gliomas such as the glioblastoma multiforme 
(GBM). Mean survival time is only eleven months after 
diagnosis in spite of surgery, radiation therapy, and 
chemotherapy. Efforts have been taken to cure 
experimental brain tumors in rats using a suicide gene 
transfer paradigm in which the herpes simplex virus 
thymidine kinase (HSVtk,  EC  2.7.1.21) gene i s  
transferred in vivo to neoplastic cells. Subsequently 
ganciclovir (GCV) is administered to animals and 
thought to be processed by HSVtk to a mono-phosphate 
which thereafter is transformed to the toxic metabolite 
ganciclovir-triphosphate through cellular kinases. This 
concept was first published and shown to be effective in 
subcutaneous tumors in 1986 (Moolton, 1986) and later 
performed successfully in intracerebral neoplasms 
(Culver et al., 1992). Since the toxic GCV metabolite is 
supposed to cross gap junctions between tumor cells not 
al1 cel ls  have to  be transfected for  total tumor 
eradication. This effect is known as the "bystander 
effect" (Ishii-Morita et al., 1997). Only few clinical 
studies have been published to date with disappointing 
results (Ram et al., 1997; Klatzmann et al., 1998; Shand 
et al., 1999; Packer et al., 2000; Trask et al., 2000). 
Different vectors have been shown to deliver genes 
sufficiently for transfection. These include viral and non- 
viral vectors.  Retroviral vectors  have long been 
considered an ideal vector for suicide gene therapy in 
cerebral tumors since they only transfect replicating cells 
(Culver et al., 1992). A number of studies have shown 
promising results in suicide gene transfer with retroviral 
vectors in cerebral tumors (Culver et al., 1992; Ram et 
al., 1993a; Barba et al., 1994; Izquierdo et al., 1995; 
Cool et al., 1996; Rainov et al., 1996; Vincent et al., 
1996b; Berenstein et al., 1999). Adenoviral vectors show 
a high transfection efficiency (Chen et al., 1994; Vincent 
et al., 1996a) but do transfect non-replicating cells as 
well (Boviatsis et al., 1994) and are associated with a 
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high degree of immunoreactivity (Kajiwara et al., 1997). 
Liposomes and other non-vira1 vectors are considered 
less-immunogenic and less-toxic (Kramm et al., 1995) 
and can hence be delivered to the tumor site in a 
repetitive or continuous manner. Because detailed 
neuropathological studies on liposomal gene transfer are 
lacking, we here thoroughly examined and compared 
histopathologically the extent of total tumor destruction, 
immunogenicity, and toxicity of various liposomal gene 
delivery systems in the F98 rat glioblastoma. 
Material and methods 
Surgical procedures and time schedule 
The operative procedures have been described in 
detail elsewhere (Zhu et al., 1996). 4 x 1 0 ~  cells of the rat 
glioblastoma cell line F98 (Ko et al., 1980) were 
stereotactically implanted into the right hemisphere of 
adult male Fischer rats 2.6 mm lateral and 1.0 mm 
frontal to the bregma, 5.0 mm deep using a Hamilton 
syringe. From a total of 175 animals eleven experimental 
and ten control groups were created, controls receiving 
either irrelevant control genes or subsequent placebo 
instead of GCV or a combination of both (Table 1). On 
day seven after tumor implantation gene constructs were 
administered intratumorally using the same coordinates 
described above either by a single administration or by 
an implanted continuous intratumoral vector delivery 
system over three days (Alzet Brain Infusion Kitl3-5 
mm, Alza, USA). Three days after completed gene 
transfer GCV was administered intraperitonally 100 
mg/kg body weightld for 14 consecutive days. On day 
24 or 27 respectively, depending on single or continuous 
pump application, animals were sacrificed, the brains 
were removed, perfused with 3% paraformaldehyde in 
ice-cold phosphate buffered solution (PBS), and 
processed histopathologically. 
Plasmids and vectors 
Three different plasmids, al1 containing the HSVtk 
gene, were used for liposomal transfection, which are 
pGlTkSvNa (Genetic Therapy Int./Novartis, USA), 
pUT649 (Cayla/Eurogentech, B), and Bk-Tk (Dr. Th. 
Blankenstein, MDC Berlin, FRG). LacZ (pUT651, 
Cayla/Eurogentech, B), encoding for B-galactosidase, 
was used as a control gene. As gene taxis, we used 
DMRIE (Felgner and Ringold, 1989), DC-Chol (Gao 
and Huang, 1991), DAC-Chol (Reszka et al., 1995), and 
DOCSPER (Groth et al., 1998). DOPE (Sigma, USA) 
was used as helper lipid in al1 cases. The molecular 
ratios used were as follows: DMRIEIDOPE 1:1, DC- 
CholIDOPE 3:2, DAC-CholIDOPE 6:4 (wlw), 
DOCSPERIDOPE 1:l (wlw). The  preparation of 
liposomes is described in detail elsewhere (Reszka et al., 
1995; Groth et al., 1998). For liposomal gene transfer a 
DNAIliposome complex of 10pg130pl was injected, 
whereas for continuous liposomal application we used a 
complex of 35pg/110pl. For retroviral gene transfer we 
Table 1. Experimental groups (upper part, groups A-K) and control groups (lower part, a-1). 
GROUP TUMOR GENE CONSTRUCT VECTOR GCV "1 "2 
A F98 pGl TkSvNa DMRIWDOPE, S GCV ¡.p. 12 12 
B F98 pUT 649 (tk) DMRIWDOPE, p GCV ¡.p. 7 6 
C F98 Bk-TK DMRIEIDOPE, S GCV ¡.p. 12 11 
D F98 pGl TkSvNa DMRIEIDOPE, p GCV ¡.p. 12 11 
E F98 pGl TkSvNa DC-Chol/DOPE, S GCV ¡.p. 11 7 
F F98 pUT 649 (tk) DAC-Chol/DOPE, p GCV ¡.p. 14 1 O 
G F98 pUT 649 (tk) DOCSPERIDOPE, p GCV ¡.p. 6 5 
H F98 AdCMV-TK adenovirus, S GCV ¡.p. 9 9 
I F98 AdCMV-TK adenovirus, p GCV ¡.p. 5 4 
J F98 TK retrovirusVPC. S GCV ¡.p. 6 4 
K F98 pUT 649 (tk) DAC-CholIDOPE, S 
c F98 LacZ DMRIWDOPE, S PBS ¡.p. 8 7 
d F98 LacZ DMRIWDOPE, p GCV ¡.p. 11 9 
e F98 AdRSV-gal adenovirus, S GCV ¡.p. 2 2 
f F98 AdRSV-gal adenovirus, S PBS ¡.p. 2 2 
g F98 TK retrovirusVPC, S PBS ¡.p. 5 5 
h F98 .l. PBS, S PBS ¡.p. 19 15 
I F98 .l. DMRIWDOPE, S PBS ¡.p. 3 3 
i F98 .l. DAC-Chol/DOPE, p PBS ¡.p. 5 5 
Abbreviations as follows (in alphabetical order): .l.: no application of vectors; ¡.p.: intraperitoneal application of GCV; ¡.t.: intratumoral application of 
GCV; n,: total number of animals; n2: nurnber of anirnals su~iving surgery and entering the study; p: vector application via microosmotic pump; S: 
single vector application via stereotactic apparatus. For abbreviations of gene constructs and vectors please refer to the Material and Methods section. 
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used lo6 vector producing cells in 50 p1 with a vira1 load 
of 4 x 1 0 ~  plaque f o r m i n ~  units (pfu); the adenoviral 
transfer was done with 10 pfu. 
Histopathological and immunohistochemical evaluation 
Brains were removed, stored at -70 QC, and cut on a 
cryostat into 7 p m  coronal slices at -20 T .  Slides were 
pretreated with poly-L-lysine (Sigma, USA). Slices from 
the site of the surgical procedure were stained following 
a standard hematox lin and eosin (HE) protocol, & embedded in Eukitt (Kindler GmbH, FRG), and 
analyzed for size and morphology of the tumor. Every 
other slice was also stained immunohistochemically 
using the APAAP method (alkaline phosphatase-anti 
alkaline phosphatase).  The following primary 
monoclonal antibodies were used in the given dilution: 
anti-CD4 (0x35, 1:50), anti-CD8 (0x8, 1:400), anti- 
CDllbIc (0x42, 1:100), anti-MHC I(Ox18, 1:400), and 
anti-MHC 11 (Hisl9, 1:200, al1 Pharmingen, USA); anti- 
T (B115-1, 1:1600) and anti-B (B115-9, 1:800, both 
Holland biotechnology bv, NL); anti-GFAP (1:100, 
Eurodiagnostika, FRG); anti-connexin 43 (Chemicon 
International Inc., USA); anti-proliferation (Ki67, 1:100, 
Novocastra Laboratories Ltd, UK); and anti-HSVtk 
(1:100, Dr. W. C. Summers, Yale University, USA, only 
group G). Sections were incubated at 4 OC in a humid 
chamber with 100 p1 solution for 16 hours. After rinsing 
sections were incubated with 50 p l  goat anti-mouse 
antibody (1:50, Jackson ImmunoResearch Laboratories, 
USA) as  secondary antibody at RT for 3 0  min. 
Incubation with the antibody-enzyme complex (APAAP 
mouse monoclonal D 651, 1:50, DAKO, DK) was done 
for 30  min at RT with 50  p l  solution per section. 
Sections were developed in a bath consisting of solutions 
A, B, and C for 10  min at RT. Component A was 
composed of 0.1 g levamisole (Sigma, USA), 62.5 m1 
0.2M propandiol (Merck-Schuchardt, FRG) and 175 m1 
0.5M tris (pH 8.7, Serva, FRG). Component B consisted 
of 0.12 g naphthol As Bi phosphate (Sigma, USA) 
solved in 1.7 m1 dimethylformamide (Serva, FRG). 
Component C contained 0.05 g sodium nitrite (Merck, 
FRG) in 1.25 m1 Aq. dest. gently stirred for 60 s with 
500 ~ 1 5 %  new fuchsin solution in 2N HCl (Neufuchsin- 
certistainB, Merck, FRG). Component C was stirred 
into component A, and component B was added. After 
developing, the s l ides were rinsed thoroughly, 
counterstained with hematoxylin, and embedded in a 
watery medium ( ~ ~ u a t e x @ ,  Merck, FRG). Tissue 
sections without application of the primary antibody 
served as negative controls for the immunoreactions, 
sections from rat lymph nodes served as positive 
controls. 
Tumor size was defined as tumor area in a coronal 
section in per cent of the right hemisphere. The slice for 
evaluation was taken exactly from the site of 
implantation, using the cortical entry of the needle track 
as marker. The same HE-stained slice was used to 
describe pattern of growth and pathologies. 
Hemorrhages were assessed using a six-point 
semiquantitative scale ('O' = no hemorrhages, '1' = low 
grade hemorrhages into tumor or into tumor cavity, '2' = 
high grade hemorrhages into tumor or into tumor cavity, 
or low grade hemorrhages into brain parenchyma, '3' = 
high grade hemorrhages into brain parenchyma of the 
contralateral hemisphere, '4' = any intratumoral 
hemorrhage with a mass effect,  '5 '  = any 
intraparenchymal hemorrhage with a mass effect, or any 
intraventricular hemorrhage). Necroses were judged 
accordingly. Criteria to describe histological parameters 
in malignant gliomas were adapted from other recent 
publications (Karkavelas et al., 1995; Coons et al., 
1997). The number of immunocompetent cells was 
assessed histologically and immunohistochemically 
using a five-point semiquantitative scale ('-' = O cells, '+' 
4 0  cells, '++' e250 cells, '+++' <lo00 cells, and '++++' 
2 1000 cells in a single coronal slide). 
Statistical calculations were performed using 
GraphPad Prism 2.0. Tumor sizes were compared using 
the unpaired t-test. Infiltration of cells and other 
histological alterations were analyzed using the Mann- 
Whitney algorithm. A 95% confidence interval was 
chosen for statistical significance (p<0.05). 
Results 
Tumor implantation was survived by 147 out of 175 
animals. Al1 deaths were due to surgery or anesthesia. 
Clinical chemistry was done on al1 animals and is 
described elsewhere (Zhu et al., 1996). Five animals 
were excluded from further analysis because of a lack of 
tumor growth. 
Controls and tumor histology 
Animals in the main control group (group h) were 
only treated with PBS. On day 24 the tumor measured 
more than 60% of the right hemisphere on the average, 
exhibiting a large scale mass effect with compression of 
the right lateral ventricle (Fig. la). In the other control 
groups reductions in tumor size were non-significant 
when compared to the PBS group (Fig. 2a). 
Tumors were highly cellular with infiltration of 
peritumoral vessel sheaths (Fig. lc) and metastasized to 
ipsilateral and contralateral subarachnoid spaces. In 
some animals residual tumors were found along the 
needle track of the inoculation procedure (Fig. lc) .  
Small to mid-sized intratumoral necroses were always 
visible. Hemorrhages into the tumor tissue were found 
regularly. However, there was no bleeding into the 
ventricles or into the subarachnoid space. The neoplastic 
cells were fusiform in shape and moderately 
polymorphic. Many cells showed atypical mitoses. 
Regularly, few macrophages were detectable, mainly in 
the neighborhood of small vessels. In some animals a 
few CD8+ lymphocytes were found. Few granulocytes 
were seen in one animal. Tumors were weakly positive 
for GFAP. 
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Flg. 1. a-h. Histopathologicai results. a-c. Therapeutic success. HE. a. Group h. Single, large tumor of the right hemisphere in a corona1 slice. The 
asterisk is placed in the right ventricle. b. Group D. Total tumor regression without any residual tumor cells in high power field examination. c. Grwp D. 
A small residual tumor is left along the needle track (arrow). Note the infiltration of the peritumoral vessel sheaths. Very clearty visible also is a 
therapeutic regression cavity in the central area of the brain parenchyma, filled with detritus and lymphocytes (arrowhead). d-e. lmmunohistochemical 
results. d. H anti-T, group C. T-cells along the margin of the regression cavity of a treated animal. e. IH anti-HSVtk, group G. HSVtk is found on day 24 
post transfection. The anowhead marks an HSVtk-positive cell. +h. Controls of immunogenicity of the different vecton used. IH anti-T. f. Group g. 
Marked immunoreaction in the retroviral control group. g. Group a. No immunoreaction in the liposomal control group. h. Group e. No immunoreaction 
in the adenoviral control group. a-d, x 20; e, x 1,000; f-h. x 400 
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Size of tumor animals; 33.3%) and D (3 of n = l l  animals; 27.3%). 
Tumor sizes were also significantly reduced in these 
In a total of ten animals, al1 in three of eleven groups when compared to the PBS control group h 
experimental groups, large regression cysts without any (adenoviral group H, n=7, p<0.01; liposomal group B, 
residual tumor cel ls  were found (Fig. l b ) .  The  n=6, p<0.001; liposomal group D, n=l l ,  pc0.001; Fig. 
percentage of animals with total tumor regression was 2a). Liposomal groups A, C, and E did not show a 
higher in the adenoviral group H (5 of n=7 animals; significant tumor size reduction. Application of the 
71.4%) than in the liposomal groups B (2 of n=6 vector via an implanted microosmotic pump (liposomal 
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group D) in comparison to single application (liposomal 
group A) yielded a significantly smaller tumor (pe0.05, 
Fig. 2a). 
lmmunogenicity and infiltration of immunocompetent 
cells 
Lymphocytes were detected by histological and 
immunohistochemical stainings with a variety of 
markers (anti-T, anti-B, anti-CD4, anti-CD8, anti-MHCI, 
and anti-MHCII). In six experimental groups the mean 
semiquanitative lymphocyte count was significantly 
elevated compared to the PBS control group h 
(liposomal group D, n= l l ,  pe0.05; liposomal group F, 
n=10,  pe0.01;  liposomal group G,  n=5, p<0.05; 
adenoviral group H, n=9, pe0.01; retroviral group J, 
n=4, pe0.05; liposomal group K, n=5, pe0.05). Arnong 
the controls only the retroviral control group g with a 
retroviral vector (n=5,  p>0.05) featured a high 
lymphocyte infiltration that was non-significantly 
elevated compared to control group h (Fig. 2a). 
Typically, lymphocytes gathered along the margin of the 
regression cavity in treated animals (Fig. Id). In almost 
al1 cases lymphocytes were CD8+, only occasionally 
were CD4+ lymphocytes found in close neighborhood to 
granulocytic accumulations. 
Macrophages were seen in most specimens either by 
HE stainings or immunohistochemical markers (e.g. 
anti-CD11 and anti-MHCII). In three experimental 
groups the mean macrophage infiltration score was 
significantly elevated compared to control group h 
(liposomal group F, n=10, pe0.05; adenoviral group H, 
n=7, pe0.05; liposomal group K, n=5, pe0.05, data not 
shown). The other groups did not show significant 
differences. Granulocytes were found in some 
experimental groups; the mean infiltration score was not 
significantly elevated in any group. 
Other neuropathology 
In two experimental groups treated with liposomal 
and adenoviral gene transfer, animals with 
intraventricular bleeding were found; the hemorrhage 
score was significantly higher in these groups compared 
to PBS control group h (lipsomal group B, n=6, pe0.05; 
adenoviral group 1, n=4, pe0.05). Other differences 
regarding hemorrhages and necroses were non- 
significant. 
Immunohistochemically HSVtk was found in tumor 
cells on day 24 post transfection (Fig. le). 
Discussion 
Our results are based on microscopic assessment of 
the brains of 142 rats in eleven experimental and ten 
control groups. Due to resources, groups did 
significantly differ in size. Groups of ne4 were excluded 
from statistical analysis and served as non-significant 
Table 2. Efficacy of gene therapy in in vivo HSVtWGCV suicide gene transfer studies in intracerebral and leptomeningeal tumors of rodents. Listed in 
chronological order and in comparison to our recent results. 
STUDY TUMOR VECTOR RESULTS 
Ram et al., 1993a 
Barba et al., 1994 
Boviatsis et al., 1994 
Chen et al., 1994 
Perez-Cruet et al., 1994 
Tapscott et al., 1994 
Izquierdo et al., 1995 
Maron et al., 1995 
Ross et al., 1995 
Cool et al., 1996 
Kramm et al., 1996b 
Maron et al., 1996 
Okada et al., 1996 
Rainov et al., 1996 
Vincent et al., 1996a 
Vincent et al., 1996b 
Kruse et al., 1997 
Quillien et al., 1997 
Berenstein et al., 1999 
Sandmair et al., 1999 
group B 
group D 
group H 
VPC 
VPC 
HSV 
ADV 
ADV 
VPC 
VPC 
in vltro t 
ADV 
VPC 
HSV 
ADV 
AAV 
VPC 
ADV 
VPC 
in vitro $ 
ADV 
VPC 
VPC 
DMRIWDOPE 
DMRIWDOPE 
ADV 
76% total regression 
40% total regression 
48% survive five months 
20% total regression 
100% survive 98 days, 75% survive 120 days 
no significant success 
100% total regression 
100% survive 30 days, 33% survive 80 days 
significant longer survival 
no significant success 
90% survive 100 days 
28-fold tumor reduction 
1 1-fold tumor reduction 
65% survive 26 days 
significant longer survival 
significant longer survival 
53% total regression 
67% total regression 
33% total regression 
no significant success 
33.3% total regression 
27.3% total regression 
71.4% total regression 
t: tumor cells were transfected with HSVtk-DNA prior to implantation; $: tumor cells were transfected with retroviral particles prior to implantation; 
AAV: adeno-associated vector; ADV: adenovirus; DMRIWDOPE: liposomal preparation; HSV: herpes simplex virus; VPC: vector-producing cells. For 
therapy protocols of groups B, D, and H please refer to Table 1. 
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trials only. Due to limited resources, PBS control groups 
for each experimental group were not done. However, 
the lack of influence of PBS on either tumor size or 
survival has been shown by a number of other 
investigators (e.g., Zhu et al., 1996). 
According to others, the F98 tumor model is only 
weakly immunogenic compared to other widely used 
malignant glial tumor models, e.g. C6 and 9L, and has a 
high invasive nature and a reliable lethality in Fisher 
rats. It is valued as one of the most reliable, highly 
malignant, and non-immunogenic rodent brain tumor 
models (Barth, 1998). 
Size of tumor and treatment eíficacy 
We used the size of the tumor after sacrifice of the 
animals on day 24 or 27, respectively, as marker for 
therapeutic efficacy. Tumor size was expressed in per 
cent of the right hemisphere in the corona1 slice. The 
slice for evaluation of the tumor size was taken from the 
site of implantation, the entry of the needle track was 
clearly visible on the cortex while preparing the frozen 
sections. Tumor growth was spherical in serial cuts of 
individual animals, hence this procedure yields a 
representative value of the tumor volume. 
For the first time, liposomes were used in our 
laboratory as gene taxis in HSVtkIGCV suicide gene 
therapy for malignant brain tumor (Zhu et al., 1996). 
Here we present a detailed neuropathological analysis of 
this study. It extends the scope of earlier studies on vira1 
transfection strategies to a significant degree (c. Table 
2). Promising results were especially achieved in 
liposomal groups B and D using DMRIEJDOPE 
liposomes. Liposomal preparations DAC-CholIDOPE 
and DOCSPER/DOPE also showed a significant tumor 
regression, however, to a somewhat lesser degree. 
Application of the vector via an implanted microosmotic 
pump yielded additional therapeutic power. 
On the other hand, we also found a significant tumor 
regression in one  of the two adenoviral groups. 
Nevertheless, this approach was only non-significantly 
superior to the liposomal approaches. Other groups that 
used adenoviral vectors for transfection as well yielded 
comparatively good results (Chen et al., 1994; Perez- 
Cruet et al., 1994; Ross et al., 1995; Maron et al., 1996; 
Vincent et al., 1996a,b; Quillien et al., 1997). 
In the small group that was treated with a retroviral 
vector (group J) only a slight tumor regression was 
noted, which stands in contradiction to  other 
publications (Ram et al., 1993a, Barba et al., 1994; 
Izquierdo et al., 1995; Rainov et al., 1996; Vincent et al., 
1996b, Berenstein et al., 1999) but is supported by others 
(Tapscott et al., 1994; Cool et al., 1996; Sandmair et al., 
1999). Although we cannot exclude that the virus titer 
might have been too small  for  highly successful 
transfection in this experiment, a retrial with VPC with a 
confirmed virus titer of 108/ml did not complete tumor 
regression either (data not shown, Dr. R. Reszka). 
Two studies were designed to directly compare 
retroviral and adenoviral transfection, but no significant 
differences were found (Boviatsis et al., 1994; Vincent et 
al., 1996b). In one study tumor cells were transfected 
with a herpes virus vector and excellent results were 
found (Kramm et al., 1996a). 
Differences between our results and those of others 
can partly be explained with the missing similarity of 
parameters for successful therapy (Table 2). Two of the 
listed studies used tumor cells that were already 
transfected prior to implantation (Maron et al., 1995; 
Kruse et al., 1997). Two other studies report survival 
rates or complete tumor regression in 100% of the 
animals (Perez-Cruet et al, 1994; Izquierdo et al., 1995). 
While the former of these reports is  based upon 
magnetic resonance imaging (MRI) and therefore 
neglects the possibility of small residual tumors, the 
latter one draws its conclusion from an experimental 
group with only four animals and therefore has to be 
treated with caution. Two studies did not show any 
significant therapeutic success (Tapscott et al., 1994; 
Cool et al., 1996). However, the authors found 
significant reduction of a subcutaneous tumor in an 
otherwise identical experimental setting and hence 
postulated that the blood-brain barrier reduces the GCV 
concentration in the intracerebral tumor (Cool et al., 
1996). Two studies examined the role of intrathecal 
metastases (Kramm et al., 1996a; Vincent et al., 1996a). 
In addition, the different time schedules have to be taken 
into account. In a couple of studies long-term survival 
rates have been evaluated, while in others, like in our 
study, animals were killed on a fixed day post tumor 
implantation. 
Histopathological alterations and infiltration of 
lymphocytes 
Only few studies demonstrate immunopathological 
alterations in the specimens (Ram et al., 1993b; Barba et 
al., 1994; Wood et al., 1994; Ross et al., 1995; Kramm et 
al., 1996b; Shine et al., 1997). Some authors describe a 
moderate edema and gliosis (Ram et al., 1994), or 
activation of microglia (Wood et al., 1994), infiltration 
of macrophages and lymphocytes (Barba et al., 1994; 
Wood et al., 1994; Shine et al., 1997), and generally 
marked leptomeningeal inflammation (Kramm et al., 
1996b). One study showed that tumor resistance 
against a second implantation of tumor cells developed 
after therapy (Barba e t  al., 1994). The  only 
neuropathological long-term study of CNS-1 tumors 
revealed a marked chronic inflammation and signs for 
loss of myelin after adenoviral-mediated transfer of 
HSVtk and subsequent administration of GCV (Dewey 
et al., 1999). Inflammation could have various causes in 
our experimental setting. The implanted tumor itself can 
be immunogenic (Tapscott et al., 1994; Barth et al., 
1998); this was not relevant in our study since control 
animals received the same tumor. During surgical 
manipulation, bacteria and viruses can be inoculated into 
the cranium. Applied vectors  can induce an 
Pathology of gene therapy in rat glioblastoma 
inflammatory immunoreaction; this was taken as a sign 
for immunogenicity of the respective vector when found 
in control animals. Lastly, when killed successfully, dead 
tumor cells and the detritus have to be removed from the 
tumor site, which also involves an immunoreaction. 
In our  study, w e  have focused on  the 
immunogenicity of the vectors used. We were especially 
interested in the irnmunogenicity of liposomal vectors. 
The lymphocyte infiltration in the liposomal controls 
was clearly similar to the score of the PBS control group 
h (groups a, b, c ,  d, i ,  and j), indicating that the 
liposomal preparations themselves did not elicit any 
detectable immunoreaction after day 24  or  27, 
respectively, and hence justifying a continuous 
application via a microosmotic pump. This concept is 
important for effective tumor control in malignant 
gliomas, because only about a third of al1 cells in human 
GBM are proliferating at a given time (Hoshino and 
Wilson, 1979). 
In treated animals, lymphocytes were only found 
along the needle track and the regression cavity. In some 
animals periventricular lymphocytes were detectable. No 
marked encephalitis was seen in any animal. 
Adenoviral vectors, HSV-vectors and allogenic VPC 
are known to be immunogenic, whereas liposomes are 
supposed to  be non-immunogenic and non-toxic 
(Kramm et  al., 1995). We did not find any 
immunoreaction in our adenoviral controls in terms of 
infiltration with lymphocytes (groups e and f), although 
the groups were too small to give this finding any 
statistical significance. We have to assume that the 
adenoviral vector titer was high enough since animals 
with total tumor regression were successfully treated 
with the same vector (group H). This finding stands in 
contrast to a publication mentioned above (Shine et al., 
1997), but is supported by others, which do not consider 
adenoviral vectors to be immunogenic (Boviatsis et al., 
1994; van der Eb et al., 1998). The adenoviruses used by 
us were cleared from any additional protein which might 
contribute to the low immunogenicity of the adenoviral 
vectors in our study. 
The first vector to be used in suicide gene transfer 
was a retroviral vector, in which only edema and gliosis 
were described as a reaction to the transfer of a marker 
gene (Ram et al., 1994). This again stands in contrast to 
our findings, since we noted marked infiltration of both 
macrophages and CD8+ lymphocytes in the retroviral 
control (group g). 
In comparison to the PBS control group h, the 
experimental groups B (DMRIEIDOPE) and 1 
(adenovirus) showed a high tendency for intraventricular 
hemorrhages and a significantly higher hemorrhage 
score. The hemorrhages in the liposomal group B are 
unclear to us. An explanation in regard to group 1 
(adenovirus) i s  the possible transfection of the 
endothelium of intraparenchymal vessels and subsequent 
destruction and rupture following GCV administration, 
for it is known that adenoviral vectors can transfect al1 
types of cells (Boviatsis et al., 1994; Perez-Cruet et al., 
1994). We however did not find transfection of 
endothelial cells. 
Ganciclovir 
The amount of GCV administered is still a matter of 
debate. For successful tumor control a sufficient 
concentration of GCV has to cross the blood-brain 
barrier to be metabolized by the intratumorally- 
expressed HSVtk. In this study 200 mglkg body 
weightld GCV for 14 days was used; in clinical studies 
usually 10 mglkg body weightld GCV is given. This 
might explain the unsatisfactory results of recent clinical 
studies. Cerebral toxicity of intraperitoneally-applied 
GCV has never been reported in previous experimental 
settings. We do not see any signs for microscopically 
evident toxicity to GCV in our study (groups b and c). 
Although direct intratumoral administration of GCV 
yielded a significant tumor regression (group K), the 
outcome was similar to experimental groups with 
intraperitoneal administration. 
Concluding remark 
Taken together, in our experimental setting, only 
tumor cells were found to have synthesized HSVtk 
protein; structures other than tumor cells were not 
damaged. Liposomes, e.g. DMRIEIDOPE, used as 
vectors for tumor gene therapy are as efficient as 
adenoviruses are. They are non-immunogenic and hence 
can be applied via a microosmotic pump or any other 
continuos application system for an even better and safer 
tumor therapy. 
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